[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Erythromycin.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be decreased when combined with Erythromycin.]
[B01AD01, streptokinase, The risk or severity of bleeding can be increased when Erythromycin is combined with Streptokinase.]
[J01EC02, sulfadiazine, The metabolism of Sulfadiazine can be decreased when combined with Erythromycin.]
[J01EC01, sulfamethoxazole, Erythromycin may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Erythromycin may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Sulpiride.]
[L01BB02, mercaptopurine, The metabolism of Mercaptopurine can be decreased when combined with Erythromycin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Erythromycin.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Erythromycin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Erythromycin.]
[B01AE07, dabigatran etexilate, The serum concentration of Dabigatran etexilate can be increased when it is combined with Erythromycin.]
[G03BA03, testosterone, The metabolism of Testosterone can be decreased when combined with Erythromycin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Tetracaine.]
[S03AA02, tetracycline, The metabolism of Tetracycline can be decreased when combined with Erythromycin.]
[N05AE05, lurasidone, The metabolism of Lurasidone can be decreased when combined with Erythromycin.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Erythromycin.]
[N04BC07, apomorphine, The metabolism of Apomorphine can be decreased when combined with Erythromycin.]
[L04AX02, thalidomide, The metabolism of Erythromycin can be increased when combined with Thalidomide.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Erythromycin.]
[R03DA04, theophylline, The therapeutic efficacy of Erythromycin can be decreased when used in combination with Theophylline.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erythromycin.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Erythromycin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Erythromycin.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Erythromycin.]
[P01AB02, tinidazole, Erythromycin may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Erythromycin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Erythromycin.]
[L01XF01, tretinoin, The metabolism of Tretinoin can be decreased when combined with Erythromycin.]
[S01BA05, triamcinolone, Erythromycin may decrease the excretion rate of Triamcinolone which could result in a higher serum level.]
[N05CD05, triazolam, The serum concentration of Triazolam can be increased when it is combined with Erythromycin.]
[R03BA07, mometasone, The metabolism of Erythromycin can be increased when combined with Mometasone.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Erythromycin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Trimethadione.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Erythromycin.]
[N06AA06, trimipramine, The serum concentration of Trimipramine can be increased when it is combined with Erythromycin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Erythromycin.]
[J01FA08, troleandomycin, The metabolism of Erythromycin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Vilazodone can be decreased when combined with Erythromycin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Erythromycin.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Erythromycin.]
[L02BX03, abiraterone, The metabolism of Abiraterone can be decreased when combined with Erythromycin.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Erythromycin.]
[J05AP03, boceprevir, The metabolism of Erythromycin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The serum concentration of Telaprevir can be increased when it is combined with Erythromycin.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be increased when it is combined with Erythromycin.]
[B01AD04, urokinase, The risk or severity of bleeding can be increased when Erythromycin is combined with Urokinase.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Erythromycin.]
[B01AF01, rivaroxaban, The risk or severity of bleeding can be increased when Erythromycin is combined with Rivaroxaban.]
[R03AC18, indacaterol, The metabolism of Indacaterol can be decreased when combined with Erythromycin.]
[B01AC24, ticagrelor, The risk or severity of bleeding can be increased when Erythromycin is combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Erythromycin is combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Erythromycin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The serum concentration of Vinblastine can be increased when it is combined with Erythromycin.]
[C04AX07, vincamine, The serum concentration of Vincamine can be increased when it is combined with Erythromycin.]
[L01CA02, vincristine, The excretion of Vincristine can be decreased when combined with Erythromycin.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Erythromycin.]
[A11HA03, vitamin E, The metabolism of Vitamin E can be decreased when combined with Erythromycin.]
[B01AA03, warfarin, The risk or severity of bleeding can be increased when Erythromycin is combined with Warfarin.]
[J05AF01, zidovudine, The metabolism of Zidovudine can be decreased when combined with Erythromycin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Erythromycin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Erythromycin.]
[L01FX05, brentuximab vedotin, The serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin.]
[L01ED01, crizotinib, The serum concentration of Crizotinib can be increased when it is combined with Erythromycin.]
[B01AE01, desirudin, The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.]
[R03DC01, zafirlukast, The serum concentration of Zafirlukast can be decreased when it is combined with Erythromycin.]
[S01XA15, ascorbic acid, The therapeutic efficacy of Erythromycin can be decreased when used in combination with Ascorbic acid.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Erythromycin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be decreased when combined with Erythromycin.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Erythromycin.]
[G04BD07, tolterodine, The metabolism of Tolterodine can be decreased when combined with Erythromycin.]
[C07AB03, atenolol, Erythromycin may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[J02AC03, voriconazole, The metabolism of Erythromycin can be decreased when combined with Voriconazole.]
[S01FA01, atropine, Erythromycin may decrease the excretion rate of Atropine which could result in a higher serum level.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Erythromycin.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Erythromycin.]
[R07AX02, ivacaftor, The metabolism of Ivacaftor can be decreased when combined with Erythromycin.]
[H02AB11, prednylidene, The serum concentration of Prednylidene can be increased when it is combined with Erythromycin.]
[L01BC05, gemcitabine, The serum concentration of Gemcitabine can be increased when it is combined with Erythromycin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Erythromycin.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Erythromycin.]
[G04BD12, mirabegron, The metabolism of Mirabegron can be decreased when combined with Erythromycin.]
[L01XG02, carfilzomib, The serum concentration of Carfilzomib can be increased when it is combined with Erythromycin.]
[V03AX03, cobicistat, The serum concentration of Erythromycin can be increased when it is combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Erythromycin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Erythromycin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The serum concentration of Bosutinib can be increased when it is combined with Erythromycin.]
[L04AA31, teriflunomide, The excretion of Erythromycin can be decreased when combined with Teriflunomide.]
[B01AX01, defibrotide, The risk or severity of bleeding can be increased when Erythromycin is combined with Defibrotide.]
[H02AA01, aldosterone, The serum concentration of Aldosterone can be increased when it is combined with Erythromycin.]
[L01EX05, regorafenib, The serum concentration of Regorafenib can be increased when it is combined with Erythromycin.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be increased when it is combined with Erythromycin.]
[J05AE04, nelfinavir, The metabolism of Erythromycin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Erythromycin.]
[C08CA13, lercanidipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Lercanidipine.]
[N06DA02, donepezil, The metabolism of Donepezil can be decreased when combined with Erythromycin.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Erythromycin.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Erythromycin.]
[G04BD10, darifenacin, The metabolism of Darifenacin can be decreased when combined with Erythromycin.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Erythromycin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Erythromycin.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Erythromycin.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Erythromycin.]
[B01AF02, apixaban, The risk or severity of bleeding can be increased when Erythromycin is combined with Apixaban.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Erythromycin.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Bencyclane.]
[A10BH04, alogliptin, The metabolism of Alogliptin can be decreased when combined with Erythromycin.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Erythromycin.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Erythromycin.]
[A10BK02, canagliflozin, The metabolism of Canagliflozin can be decreased when combined with Erythromycin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Gemifloxacin.]
[M04AB03, benzbromarone, Erythromycin may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Tegaserod can be increased when it is combined with Erythromycin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Benzocaine.]
[J02AX04, caspofungin, The excretion of Caspofungin can be decreased when combined with Erythromycin.]
[M01AH01, celecoxib, Celecoxib may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Erythromycin.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Erythromycin.]
[L01EC02, dabrafenib, The serum concentration of Erythromycin can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Benzyl alcohol.]
[L01EB03, afatinib, The serum concentration of Afatinib can be increased when it is combined with Erythromycin.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be decreased when combined with Erythromycin.]
[J05AJ03, dolutegravir, The serum concentration of Dolutegravir can be increased when it is combined with Erythromycin.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Erythromycin.]
[A05AA03, cholic acid, Erythromycin may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[C02KX04, macitentan, The metabolism of Macitentan can be decreased when combined with Erythromycin.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Erythromycin.]
[N06AX26, vortioxetine, The metabolism of Vortioxetine can be decreased when combined with Erythromycin.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be decreased when combined with Erythromycin.]
[J05AP05, simeprevir, Simeprevir may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[J05AP08, sofosbuvir, The serum concentration of Sofosbuvir can be increased when it is combined with Erythromycin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Erythromycin.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Erythromycin.]
[A16AA07, metreleptin, The metabolism of Erythromycin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Erythromycin can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The serum concentration of Betamethasone can be increased when it is combined with Erythromycin.]
[B01AE03, argatroban, The risk or severity of bleeding can be increased when Erythromycin is combined with Argatroban.]
[C10AB02, bezafibrate, The metabolism of Bezafibrate can be decreased when combined with Erythromycin.]
[L04AC11, siltuximab, The metabolism of Erythromycin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The serum concentration of Ceritinib can be increased when it is combined with Erythromycin.]
[B01AC26, vorapaxar, The risk or severity of bleeding can be increased when Erythromycin is combined with Vorapaxar.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Erythromycin.]
[B01AA07, acenocoumarol, The risk or severity of bleeding can be increased when Erythromycin is combined with Acenocoumarol.]
[L01XH04, belinostat, The serum concentration of Belinostat can be increased when it is combined with Erythromycin.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Erythromycin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Erythromycin.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be decreased when combined with Erythromycin.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Erythromycin.]
[A06AH03, naloxegol, The serum concentration of Naloxegol can be increased when it is combined with Erythromycin.]
[A11HA08, tocophersolan, The metabolism of Tocofersolan can be decreased when combined with Erythromycin.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Erythromycin.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Erythromycin.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Erythromycin.]
[B01AA01, dicumarol, The risk or severity of bleeding can be increased when Erythromycin is combined with Dicoumarol.]
[B01AF03, edoxaban, The serum concentration of Edoxaban can be increased when it is combined with Erythromycin.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Erythromycin.]
[L04AC10, secukinumab, The metabolism of Erythromycin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Erythromycin.]
[L01EX08, lenvatinib, Lenvatinib may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Erythromycin.]
[J05AP07, daclatasvir, The metabolism of Daclatasvir can be decreased when combined with Erythromycin.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Erythromycin.]
[B01AA11, tioclomarol, The risk or severity of bleeding can be increased when Erythromycin is combined with Tioclomarol.]
[C01EB17, ivabradine, The metabolism of Ivabradine can be decreased when combined with Erythromycin.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Erythromycin.]
[A07DA06, eluxadoline, The serum concentration of Eluxadoline can be increased when it is combined with Erythromycin.]
[B01AC25, cangrelor, The risk or severity of bleeding can be increased when Erythromycin is combined with Cangrelor.]
[N05AX16, brexpiprazole, The metabolism of Brexpiprazole can be decreased when combined with Erythromycin.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Erythromycin.]
[A04AD14, rolapitant, The metabolism of Rolapitant can be decreased when combined with Erythromycin.]
[G02CX02, flibanserin, The metabolism of Flibanserin can be decreased when combined with Erythromycin.]
[N05AX15, cariprazine, The metabolism of Cariprazine can be decreased when combined with Erythromycin.]
[A02BC03, lansoprazole, The metabolism of Lansoprazole can be decreased when combined with Erythromycin.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Erythromycin.]
[J02AC05, isavuconazole, The metabolism of Isavuconazole can be decreased when combined with Erythromycin.]
[L01EB04, osimertinib, The serum concentration of Osimertinib can be increased when it is combined with Erythromycin.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Erythromycin.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Erythromycin.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Erythromycin.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Erythromycin.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Erythromycin.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Erythromycin.]
[J05AP10, elbasvir, The metabolism of Elbasvir can be decreased when combined with Erythromycin.]
[J05AP11, grazoprevir, The metabolism of Grazoprevir can be decreased when combined with Erythromycin.]
[N03AX23, brivaracetam, The metabolism of Brivaracetam can be decreased when combined with Erythromycin.]
[L01XX52, venetoclax, The serum concentration of Venetoclax can be increased when it is combined with Erythromycin.]
[N04BC01, bromocriptine, Erythromycin may increase the vasoconstricting activities of Bromocriptine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erythromycin.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Erythromycin is combined with Amlodipine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Erythromycin.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Erythromycin is combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Erythromycin.]
[N07BC01, buprenorphine, The metabolism of Buprenorphine can be decreased when combined with Erythromycin.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Erythromycin.]
[N05BE01, buspirone, The serum concentration of Buspirone can be increased when it is combined with Erythromycin.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Erythromycin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Erythromycin.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Erythromycin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Erythromycin can be decreased when combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Erythromycin.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Erythromycin.]
[N06BC01, caffeine, The metabolism of Caffeine can be decreased when combined with Erythromycin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Oxybuprocaine.]
[D05AX03, calcitriol, The metabolism of Calcitriol can be decreased when combined with Erythromycin.]
[J05AE09, tipranavir, The metabolism of Erythromycin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, The metabolism of Valbenazine can be decreased when combined with Erythromycin.]
[L04AB02, infliximab, The metabolism of Erythromycin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Erythromycin can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Erythromycin.]
[N04BD03, safinamide, The metabolism of Safinamide can be decreased when combined with Erythromycin.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Erythromycin.]
[B01AF04, betrixaban, The serum concentration of Betrixaban can be increased when it is combined with Erythromycin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Erythromycin.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Erythromycin.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Erythromycin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Erythromycin.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Erythromycin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.]
[C07AB07, bisoprolol, The metabolism of Bisoprolol can be decreased when combined with Erythromycin.]
[J05AG03, efavirenz, The metabolism of Erythromycin can be decreased when combined with Efavirenz.]
[V03AB23, acetylcysteine, The therapeutic efficacy of Acetylcysteine can be decreased when used in combination with Erythromycin.]
[N05CD09, brotizolam, The metabolism of Brotizolam can be decreased when combined with Erythromycin.]
[R03BA02, budesonide, The serum concentration of Budesonide can be increased when it is combined with Erythromycin.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.]
[J05AX18, letermovir, Letermovir may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Erythromycin is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Ertugliflozin can be increased when it is combined with Erythromycin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Erythromycin.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Macimorelin.]
[L02BB05, apalutamide, The metabolism of Erythromycin can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be decreased when combined with Erythromycin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Carbinoxamine.]
[C07AG02, carvedilol, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Carvedilol.]
[B02BX09, fostamatinib, The metabolism of Fostamatinib can be decreased when combined with Erythromycin.]
[N03AX24, cannabidiol, The metabolism of Cannabidiol can be decreased when combined with Erythromycin.]
[B02BX08, avatrombopag, The serum concentration of Avatrombopag can be increased when it is combined with Erythromycin.]
[L04AA37, baricitinib, The metabolism of Baricitinib can be decreased when combined with Erythromycin.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Erythromycin.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Erythromycin.]
[H01CC03, elagolix, The serum concentration of Elagolix can be increased when it is combined with Erythromycin.]
[L01XX62, ivosidenib, The metabolism of Ivosidenib can be decreased when combined with Erythromycin.]
[N03AX17, stiripentol, The metabolism of Erythromycin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Lusutrombopag can be increased when it is combined with Erythromycin.]
[J05AG06, doravirine, The metabolism of Doravirine can be decreased when combined with Erythromycin.]
[J01AA13, eravacycline, The metabolism of Eravacycline can be decreased when combined with Erythromycin.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Erythromycin.]
[L01EB07, dacomitinib, The serum concentration of Dacomitinib can be increased when it is combined with Erythromycin.]
[J01AA15, omadacycline, The serum concentration of Omadacycline can be increased when it is combined with Erythromycin.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Erythromycin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Chloroprocaine.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Erythromycin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Erythromycin.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Erythromycin.]
[R03BB08, revefenacin, Erythromycin may decrease the excretion rate of Revefenacin which could result in a higher serum level.]
[L01ED05, lorlatinib, The metabolism of Lorlatinib can be decreased when combined with Erythromycin.]
[L04AA39, emapalumab, The metabolism of Erythromycin can be increased when combined with Emapalumab.]
[L01EX12, larotrectinib, The metabolism of Larotrectinib can be decreased when combined with Erythromycin.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Amifampridine.]
[A06AX05, prucalopride, The serum concentration of Erythromycin can be increased when it is combined with Prucalopride.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Erythromycin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Erythromycin.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Erythromycin.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Erythromycin.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Erythromycin is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Erythromycin can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Erythromycin.]
[N05BA09, clobazam, The metabolism of Clobazam can be decreased when combined with Erythromycin.]
[H02AB14, cloprednol, The serum concentration of Cloprednol can be increased when it is combined with Erythromycin.]
[C09CA06, candesartan, The excretion of Erythromycin can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Erythromycin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The serum concentration of Cortivazol can be increased when it is combined with Erythromycin.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be decreased when combined with Erythromycin.]
[L01FX14, polatuzumab vedotin, The metabolism of Polatuzumab vedotin can be decreased when combined with Erythromycin.]
[J01DC04, cefaclor, Erythromycin may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[L01XX66, selinexor, The metabolism of Selinexor can be decreased when combined with Erythromycin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Erythromycin.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be decreased when combined with Erythromycin.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Erythromycin.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.]
[L04AA44, upadacitinib, The metabolism of Upadacitinib can be decreased when combined with Erythromycin.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Erythromycin.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be decreased when combined with Erythromycin.]
[N07XX11, pitolisant, The serum concentration of Erythromycin can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The serum concentration of Pretomanid can be increased when it is combined with Erythromycin.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Erythromycin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Erythromycin.]
[G04BE04, yohimbine, The metabolism of Yohimbine can be decreased when combined with Erythromycin.]
[J01XX09, daptomycin, The serum concentration of Daptomycin can be increased when it is combined with Erythromycin.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be decreased when combined with Erythromycin.]
[H02AB13, deflazacort, The serum concentration of Deflazacort can be increased when it is combined with Erythromycin.]
[G03DB05, demegestone, The metabolism of Demegestone can be decreased when combined with Erythromycin.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Erythromycin.]
[N02CC08, lasmiditan, The serum concentration of Lasmiditan can be increased when it is combined with Erythromycin.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Erythromycin.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be decreased when combined with Erythromycin.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Erythromycin.]
[N03AX25, cenobamate, The serum concentration of Erythromycin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Ubrogepant can be increased when it is combined with Erythromycin.]
[L01FX13, enfortumab vedotin, The metabolism of Enfortumab vedotin can be decreased when combined with Erythromycin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Erythromycin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dexchlorpheniramine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Erythromycin.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be increased when it is combined with Erythromycin.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Erythromycin.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Erythromycin.]
[N02CD06, rimegepant, The serum concentration of Rimegepant can be increased when it is combined with Erythromycin.]
[C10AX15, bempedoic acid, The excretion of Erythromycin can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The metabolism of Remdesivir can be decreased when combined with Erythromycin.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Erythromycin.]
[H02CA02, osilodrostat, The metabolism of Osilodrostat can be decreased when combined with Erythromycin.]
[J05AE05, amprenavir, The metabolism of Erythromycin can be decreased when combined with Amprenavir.]
[G04CB02, dutasteride, The metabolism of Dutasteride can be decreased when combined with Erythromycin.]
[L01EE04, selumetinib, The serum concentration of Selumetinib can be increased when it is combined with Erythromycin.]
[G03DB08, dienogest, The metabolism of Dienogest can be decreased when combined with Erythromycin.]
[N02AA08, dihydrocodeine, The metabolism of Dihydrocodeine can be decreased when combined with Erythromycin.]
[N02CC06, eletriptan, The metabolism of Eletriptan can be decreased when combined with Erythromycin.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Erythromycin.]
[L01XF03, bexarotene, The metabolism of Bexarotene can be decreased when combined with Erythromycin.]
[C08CA16, clevidipine, The metabolism of Clevidipine can be decreased when combined with Erythromycin.]
[C01BD07, dronedarone, The serum concentration of Dronedarone can be increased when it is combined with Erythromycin.]
[S03AA08, chloramphenicol, The therapeutic efficacy of Erythromycin can be decreased when used in combination with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Erythromycin.]
[L01EN02, pemigatinib, The metabolism of Pemigatinib can be decreased when combined with Erythromycin.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Erythromycin.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be increased when it is combined with Erythromycin.]
[D07XB03, fluprednidene, The metabolism of Fluprednidene can be decreased when combined with Erythromycin.]
[L01EX19, ripretinib, The metabolism of Ripretinib can be decreased when combined with Erythromycin.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be increased when it is combined with Erythromycin.]
[B01AE02, lepirudin, The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Erythromycin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Dyclonine.]
[L01XX69, lurbinectedin, The serum concentration of Lurbinectedin can be increased when it is combined with Erythromycin.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Erythromycin.]
[R06AX22, ebastine, The metabolism of Ebastine can be decreased when combined with Erythromycin.]
[J05AX29, fostemsavir, The metabolism of Fostemsavir can be decreased when combined with Erythromycin.]
[L01FX15, belantamab mafodotin, Erythromycin may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L04AC19, satralizumab, The serum concentration of Erythromycin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be increased when it is combined with Erythromycin.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Pralsetinib can be increased when it is combined with Erythromycin.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, Chlorpromazine may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Erythromycin.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Erythromycin.]
[A11CC05, cholecalciferol, The metabolism of Cholecalciferol can be decreased when combined with Erythromycin.]
[V04CK02, cholecystokinin, The excretion of Cholecystokinin can be decreased when combined with Erythromycin.]
[N06BX18, vinpocetine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Vinpocetine.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be decreased when combined with Erythromycin.]
[B06AC06, berotralstat, The serum concentration of Berotralstat can be increased when it is combined with Erythromycin.]
[A16AX20, lonafarnib, The metabolism of Erythromycin can be decreased when combined with Lonafarnib.]
[L02BX04, relugolix, The serum concentration of Relugolix can be increased when it is combined with Erythromycin.]
[L04AD03, voclosporin, The metabolism of Voclosporin can be decreased when combined with Erythromycin.]
[P03AX07, abametapir, The serum concentration of Erythromycin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Tepotinib can be increased when it is combined with Erythromycin.]
[V03AF12, trilaciclib, The serum concentration of Trilaciclib can be increased when it is combined with Erythromycin.]
[N03AX10, felbamate, The metabolism of Felbamate can be decreased when combined with Erythromycin.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Erythromycin.]
[G04CB01, finasteride, The metabolism of Finasteride can be decreased when combined with Erythromycin.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Erythromycin.]
[R03BA03, flunisolide, The serum concentration of Flunisolide can be increased when it is combined with Erythromycin.]
[S01JA01, fluorescein, Erythromycin may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Erythromycin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Erythromycin.]
[L01EK03, tivozanib, The serum concentration of Tivozanib can be increased when it is combined with Erythromycin.]
[L01FX22, loncastuximab tesirine, The serum concentration of Loncastuximab tesirine can be increased when it is combined with Erythromycin.]
[A02BA01, cimetidine, Cimetidine may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Erythromycin can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Erythromycin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Citalopram.]
[J02AX07, ibrexafungerp, The metabolism of Ibrexafungerp can be decreased when combined with Erythromycin.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Erythromycin.]
[L04AA48, belumosudil, The metabolism of Belumosudil can be decreased when combined with Erythromycin.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Erythromycin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mobocertinib.]
[L01FX23, tisotumab vedotin, The metabolism of Tisotumab vedotin can be decreased when combined with Erythromycin.]
[N02CD07, atogepant, The serum concentration of Atogepant can be increased when it is combined with Erythromycin.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Erythromycin.]
[L04AA59, avacopan, The metabolism of Avacopan can be decreased when combined with Erythromycin.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Clemastine.]
[A10BB12, glimepiride, Erythromycin may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[J01FF01, clindamycin, The therapeutic efficacy of Erythromycin can be decreased when used in combination with Clindamycin.]
[N06AX25, St. John's wort extract, The metabolism of Erythromycin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Asciminib can be decreased when combined with Erythromycin.]
[L02BG06, exemestane, The metabolism of Exemestane can be decreased when combined with Erythromycin.]
[J05AX10, maribavir, The metabolism of Maribavir can be decreased when combined with Erythromycin.]
[J04BA01, clofazimine, The metabolism of Erythromycin can be decreased when combined with Clofazimine.]
[B01AD11, tenecteplase, The risk or severity of bleeding can be increased when Erythromycin is combined with Tenecteplase.]
[C10AB01, clofibrate, The metabolism of Clofibrate can be decreased when combined with Erythromycin.]
[B06AX04, mitapivat, The metabolism of Mitapivat can be decreased when combined with Erythromycin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The serum concentration of Pacritinib can be increased when it is combined with Erythromycin.]
[G03GB02, clomiphene, The serum concentration of Clomifene can be increased when it is combined with Erythromycin.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Erythromycin.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be decreased when combined with Erythromycin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Erythromycin.]
[J05AB17, brincidofovir, The serum concentration of Brincidofovir can be increased when it is combined with Erythromycin.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Erythromycin.]
[A02BC08, vonoprazan, The metabolism of Vonoprazan can be decreased when combined with Erythromycin.]
[A05BA08, glycyrrhizic acid, Erythromycin may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05BA21, clotiazepam, The metabolism of Clotiazepam can be decreased when combined with Erythromycin.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Futibatinib can be increased when it is combined with Erythromycin.]
[H01AC08, somatrogon, The metabolism of Erythromycin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Cocaine.]
[M09AX11, palovarotene, The metabolism of Palovarotene can be decreased when combined with Erythromycin.]
[L04AC21, bimekizumab, The metabolism of Erythromycin can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The metabolism of Codeine can be decreased when combined with Erythromycin.]
[M04AC01, colchicine, The serum concentration of Colchicine can be increased when it is combined with Erythromycin.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Erythromycin.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Erythromycin.]
[J01FA15, telithromycin, The metabolism of Erythromycin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Erythromycin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Desloratadine.]
[M01AH03, valdecoxib, The metabolism of Valdecoxib can be decreased when combined with Erythromycin.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be increased when it is combined with Erythromycin.]
[N02CC05, almotriptan, The metabolism of Almotriptan can be decreased when combined with Erythromycin.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Erythromycin.]
[J02AC02, itraconazole, The metabolism of Erythromycin can be decreased when combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Bemiparin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Ketazolam can be decreased when combined with Erythromycin.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Erythromycin can be decreased when combined with Posaconazole.]
[A02BC05, esomeprazole, The metabolism of Esomeprazole can be decreased when combined with Erythromycin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Erythromycin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Erythromycin.]
[S01BA03, cortisone, The serum concentration of Cortisone can be increased when it is combined with Erythromycin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Lomefloxacin.]
[R06AX13, loratadine, Erythromycin may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[C08CA11, manidipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Manidipine.]
[H02AB15, meprednisone, The serum concentration of Meprednisone can be increased when it is combined with Erythromycin.]
[R06AD07, mequitazine, The risk or severity of ventricular arrhythmias and torsade de pointes can be increased when Erythromycin is combined with Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Adenosine.]
[C04AX01, cyclandelate, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Erythromycin.]
[C03DA04, eplerenone, The metabolism of Eplerenone can be decreased when combined with Erythromycin.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Melperone.]
[J01FA03, midecamycin, The metabolism of Midecamycin can be decreased when combined with Erythromycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Tenofovir disoproxil can be increased when it is combined with Erythromycin.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Erythromycin.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Erythromycin.]
[N06BA07, modafinil, The metabolism of Modafinil can be decreased when combined with Erythromycin.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Erythromycin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Erythromycin.]
[C10AA07, rosuvastatin, The serum concentration of Rosuvastatin can be decreased when it is combined with Erythromycin.]
[C03XA02, conivaptan, The metabolism of Erythromycin can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Vardenafil can be increased when it is combined with Erythromycin.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Erythromycin.]
[L01DA01, dactinomycin, The serum concentration of Dactinomycin can be increased when it is combined with Erythromycin.]
[G03XA01, danazol, The metabolism of Erythromycin can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapsone can be decreased when combined with Erythromycin.]
[L01DB02, daunorubicin, Erythromycin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[A04AD11, nabilone, The metabolism of Nabilone can be decreased when combined with Erythromycin.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Erythromycin.]
[N06AX06, nefazodone, The metabolism of Erythromycin can be decreased when combined with Nefazodone.]
[N03AG06, tiagabine, The metabolism of Tiagabine can be decreased when combined with Erythromycin.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be decreased when combined with Erythromycin.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Erythromycin.]
[M03AC11, cisatracurium, Erythromycin may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, The risk or severity of bleeding can be increased when Erythromycin is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Solifenacin can be decreased when combined with Erythromycin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Erythromycin.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be increased when it is combined with Erythromycin.]
[C09XA02, aliskiren, The metabolism of Aliskiren can be decreased when combined with Erythromycin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The metabolism of Erythromycin can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The serum concentration of Dexamethasone can be increased when it is combined with Erythromycin.]
[G04BD04, oxybutynin, The metabolism of Oxybutynin can be decreased when combined with Erythromycin.]
[L04AB04, adalimumab, The metabolism of Erythromycin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Gefitinib can be decreased when combined with Erythromycin.]
[R05DA09, dextromethorphan, The metabolism of Dextromethorphan can be decreased when combined with Erythromycin.]
[N03AC01, paramethadione, The metabolism of Paramethadione can be decreased when combined with Erythromycin.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Erythromycin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Erythromycin.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Erythromycin.]
[N05BA01, diazepam, The metabolism of Diazepam can be decreased when combined with Erythromycin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Cinchocaine.]
[S01BC03, diclofenac, Erythromycin may decrease the excretion rate of Diclofenac which could result in a higher serum level.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Erythromycin.]
[C02DG01, pinacidil, The metabolism of Pinacidil can be decreased when combined with Erythromycin.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Pinaverium.]
[A10BG03, pioglitazone, The metabolism of Pioglitazone can be decreased when combined with Erythromycin.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Erythromycin.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Erythromycin.]
[L02AA01, diethylstilbestrol, Erythromycin may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Erythromycin may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[D07XC04, diflucortolone, The metabolism of Difluocortolone can be decreased when combined with Erythromycin.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be increased when it is combined with Erythromycin.]
[C01AA05, digoxin, The serum concentration of Digoxin can be increased when it is combined with Erythromycin.]
[C10AX09, ezetimibe, Erythromycin may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Erythromycin may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Erythromycin may increase the vasoconstricting activities of Dihydroergotamine.]
[J05AE08, atazanavir, The metabolism of Erythromycin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Erythromycin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of adverse effects can be increased when Erythromycin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dimenhydrinate.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Erythromycin.]
[G02AD02, dinoprostone, The excretion of Dinoprostone can be decreased when combined with Erythromycin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Erythromycin.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Diphenhydramine.]
[N05CD10, quazepam, The metabolism of Quazepam can be decreased when combined with Erythromycin.]
[B01AC07, dipyridamole, The risk or severity of bleeding can be increased when Erythromycin is combined with Dipyridamole.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding can be increased when Erythromycin is combined with Drotrecogin alfa.]
[A03FA02, cisapride, The serum concentration of Cisapride can be increased when it is combined with Erythromycin.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Erythromycin.]
[C01BA03, disopyramide, Erythromycin may increase the QTc-prolonging activities of Disopyramide.]
[P03AA04, disulfiram, Erythromycin may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[S02AA12, rifamycin SV, The metabolism of Erythromycin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Erythromycin can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The serum concentration of Rifaximin can be increased when it is combined with Erythromycin.]
[N05AX08, risperidone, The metabolism of Risperidone can be decreased when combined with Erythromycin.]
[R06AE09, levocetirizine, The metabolism of Levocetirizine can be decreased when combined with Erythromycin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Erythromycin.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Erythromycin.]
[A04AD12, aprepitant, The metabolism of Aprepitant can be decreased when combined with Erythromycin.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Erythromycin.]
[L01XG01, bortezomib, The serum concentration of Bortezomib can be increased when it is combined with Erythromycin.]
[J05AE07, fosamprenavir, The metabolism of Fosamprenavir can be decreased when combined with Erythromycin.]
[G04BE08, tadalafil, The metabolism of Tadalafil can be decreased when combined with Erythromycin.]
[C02KX02, ambrisentan, The metabolism of Ambrisentan can be decreased when combined with Erythromycin.]
[C01EB18, ranolazine, The serum concentration of Ranolazine can be increased when it is combined with Erythromycin.]
[R03AC12, salmeterol, The serum concentration of Salmeterol can be increased when it is combined with Erythromycin.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Erythromycin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Erythromycin.]
[L01DB01, doxorubicin, The serum concentration of Doxorubicin can be increased when it is combined with Erythromycin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Erythromycin.]
[N06AB06, sertraline, The metabolism of Sertraline can be decreased when combined with Erythromycin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Erythromycin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Droperidol.]
[A08AA10, sibutramine, The metabolism of Sibutramine can be decreased when combined with Erythromycin.]
[C10AA01, simvastatin, The serum concentration of Simvastatin can be increased when it is combined with Erythromycin.]
[G03DB01, dydrogesterone, The metabolism of Dydrogesterone can be decreased when combined with Erythromycin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Sultopride.]
[N02CC01, sumatriptan, The excretion of Sumatriptan can be decreased when combined with Erythromycin.]
[C07AB13, talinolol, The serum concentration of Talinolol can be increased when it is combined with Erythromycin.]
[H01AA01, corticotropin, The serum concentration of Corticotropin can be increased when it is combined with Erythromycin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Erythromycin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Terodiline.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Erythromycin.]
[C09AA02, enalapril, The excretion of Enalapril can be decreased when combined with Erythromycin.]
[M01AG02, tolfenamic acid, The metabolism of Tolfenamic acid can be decreased when combined with Erythromycin.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Erythromycin.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Toremifene.]
[C03CA04, torsemide, The excretion of Torasemide can be decreased when combined with Erythromycin.]
[B01AC18, triflusal, The risk or severity of bleeding can be increased when Erythromycin is combined with Triflusal.]
[H02CA01, trilostane, The serum concentration of Trilostane can be increased when it is combined with Erythromycin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Erythromycin.]
[C05CA04, troxerutin, The risk or severity of bleeding can be increased when Erythromycin is combined with Troxerutin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Erythromycin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Erythromycin.]
[S01GX10, epinastine, The metabolism of Epinastine can be decreased when combined with Erythromycin.]
[N06AX16, venlafaxine, The metabolism of Venlafaxine can be decreased when combined with Erythromycin.]
[S01GA03, xylometazoline, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Barnidipine.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Erythromycin.]
[M01AB04, zomepirac, The metabolism of Zomepirac can be decreased when combined with Erythromycin.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Zonisamide.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Erythromycin.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Erythromycin.]
[B01AD03, anistreplase, The risk or severity of bleeding can be increased when Erythromycin is combined with Anistreplase.]
[C02AC02, guanfacine, The metabolism of Guanfacine can be decreased when combined with Erythromycin.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Erythromycin.]
[G02AB03, ergonovine, Erythromycin may increase the vasoconstricting activities of Ergometrine.]
[C04AE01, ergoloid mesylates, USP, Erythromycin may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Erythromycin can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Valproic acid.]
[S01AA13, fusidic acid, Fusidic acid may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Erythromycin.]
[S02BA08, fluocinolone acetonide, The metabolism of Fluocinolone acetonide can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The serum concentration of Estazolam can be increased when it is combined with Erythromycin.]
[A02BC02, pantoprazole, The metabolism of Pantoprazole can be decreased when combined with Erythromycin.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Erythromycin.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Erythromycin.]
[L01XX11, estramustine, The metabolism of Estramustine can be decreased when combined with Erythromycin.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Erythromycin.]
[R03BA09, fluticasone furoate, The metabolism of Fluticasone furoate can be decreased when combined with Erythromycin.]
[R03BA05, fluticasone, The metabolism of Fluticasone can be decreased when combined with Erythromycin.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Erythromycin.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Ethosuximide.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Meloxicam.]
[S01XA06, ethylmorphine, The metabolism of Ethylmorphine can be decreased when combined with Erythromycin.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Etidocaine.]
[L01CB01, etoposide, The serum concentration of Etoposide can be increased when it is combined with Erythromycin.]
[N05AE03, sertindole, The metabolism of Sertindole can be decreased when combined with Erythromycin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Erythromycin.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Erythromycin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Erythromycin.]
[R06AX12, terfenadine, The serum concentration of Terfenadine can be increased when it is combined with Erythromycin.]
[N06AB08, fluvoxamine, Erythromycin may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Erythromycin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Erythromycin.]
[C10AA03, pravastatin, The risk or severity of myopathy and rhabdomyolysis can be increased when Erythromycin is combined with Pravastatin.]
[B05AA05, dextran, The risk or severity of bleeding can be increased when Erythromycin is combined with Dextran.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Erythromycin.]
[A16AA01, levocarnitine, The excretion of Erythromycin can be decreased when combined with Levocarnitine.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Erythromycin.]
[C08CA02, felodipine, Erythromycin may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[C08EA01, fendiline, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Fendiline.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Erythromycin.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Erythromycin.]
[B01AD05, plasmin, The risk or severity of bleeding can be increased when Erythromycin is combined with Fibrinolysin.]
[N07AX03, cevimeline, The metabolism of Cevimeline can be decreased when combined with Erythromycin.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Flecainide.]
[J01CF05, floxacillin, Erythromycin may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, Fluconazole may increase the QTc-prolonging and arrhythmogenic activities of Erythromycin.]
[H02AA02, fludrocortisone, The serum concentration of Fludrocortisone can be increased when it is combined with Erythromycin.]
[D07XB01, flumethasone, The metabolism of Flumethasone can be decreased when combined with Erythromycin.]
[N07CA03, flunarizine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Flunitrazepam can be decreased when combined with Erythromycin.]
[D07AC08, fluocinonide, The metabolism of Fluocinonide can be decreased when combined with Erythromycin.]
[H02AB03, fluocortolone, The metabolism of Fluocortolone can be decreased when combined with Erythromycin.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Erythromycin.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Erythromycin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Flupentixol.]
[N05CD01, flurazepam, The metabolism of Flurazepam can be decreased when combined with Erythromycin.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Erythromycin.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Erythromycin.]
[J05AE10, darunavir, The metabolism of Erythromycin can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The metabolism of Eszopiclone can be decreased when combined with Erythromycin.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Galantamine can be decreased when combined with Erythromycin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Gallopamil.]
[C10AB04, gemfibrozil, The metabolism of Gemfibrozil can be decreased when combined with Erythromycin.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Erythromycin.]
[L01EA02, dasatinib, The serum concentration of Dasatinib can be increased when it is combined with Erythromycin.]
[N04BC06, cabergoline, Erythromycin may increase the vasoconstricting activities of Cabergoline.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Erythromycin.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Erythromycin.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Methsuximide.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be decreased when combined with Erythromycin.]
[N01AH02, alfentanil, The serum concentration of Alfentanil can be increased when it is combined with Erythromycin.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Erythromycin.]
[A10BB01, glyburide, Erythromycin may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[A10BB07, glipizide, Erythromycin may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Erythromycin.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Erythromycin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Erythromycin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Erythromycin.]
[B01AA12, fluindione, The risk or severity of bleeding can be increased when Erythromycin is combined with Fluindione.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Erythromycin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Erythromycin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Quetiapine.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be decreased when combined with Erythromycin.]
[C09CA01, losartan, Erythromycin may decrease the excretion rate of Losartan which could result in a higher serum level.]
[S01XA14, heparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Heparin.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Erythromycin.]
[A07EC02, mesalamine, The excretion of Mesalazine can be decreased when combined with Erythromycin.]
[J05AG01, nevirapine, The metabolism of Nevirapine can be decreased when combined with Erythromycin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Erythromycin.]
[R05DA03, hydrocodone, The metabolism of Hydrocodone can be decreased when combined with Erythromycin.]
[S02BA01, hydrocortisone, The serum concentration of Hydrocortisone can be increased when it is combined with Erythromycin.]
[G04BD06, propiverine, The metabolism of Propiverine can be decreased when combined with Erythromycin.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Erythromycin.]
[G03DA03, 17-alpha-hydroxyprogesterone, The metabolism of Hydroxyprogesterone can be decreased when combined with Erythromycin.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Rifabutin can be decreased when combined with Erythromycin.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Erythromycin.]
[B05CB02, sodium citrate, The risk or severity of bleeding can be increased when Erythromycin is combined with Sodium citrate.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Erythromycin.]
[N01AH03, sufentanil, The metabolism of Sufentanil can be decreased when combined with Erythromycin.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Erythromycin.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Erythromycin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Erythromycin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Erythromycin.]
[C03BA11, indapamide, The metabolism of Indapamide can be decreased when combined with Erythromycin.]
[S01BC01, indomethacin, Erythromycin may decrease the excretion rate of Indomethacin which could result in a higher serum level.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be decreased when combined with Erythromycin.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Erythromycin.]
[N05BA12, alprazolam, The serum concentration of Alprazolam can be increased when it is combined with Erythromycin.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Erythromycin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Erythromycin.]
[C10AA06, cerivastatin, Erythromycin may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Anagrelide.]
[V03AB01, ipecac, The metabolism of Ipecac can be decreased when combined with Erythromycin.]
[P01AX06, atovaquone, The metabolism of Atovaquone can be decreased when combined with Erythromycin.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Erythromycin.]
[J04AC01, isoniazid, The metabolism of Erythromycin can be decreased when combined with Isoniazid.]
[D10BA01, isotretinoin, The metabolism of Isotretinoin can be decreased when combined with Erythromycin.]
[P02CF01, ivermectin, The metabolism of Ivermectin can be decreased when combined with Erythromycin.]
[B01AE06, bivalirudin, The risk or severity of bleeding can be increased when Erythromycin is combined with Bivalirudin.]
[N06AX18, reboxetine, The metabolism of Reboxetine can be decreased when combined with Erythromycin.]
[L04AC07, tocilizumab, The metabolism of Erythromycin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The metabolism of Ketamine can be decreased when combined with Erythromycin.]
[B01AC22, prasugrel, The risk or severity of bleeding can be increased when Erythromycin is combined with Prasugrel.]
[J02AB02, ketoconazole, The metabolism of Erythromycin can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Erythromycin.]
[L04AA24, abatacept, The metabolism of Erythromycin can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mizolastine.]
[N04BC09, rotigotine, The metabolism of Rotigotine can be decreased when combined with Erythromycin.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Nalidixic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Erythromycin.]
[J05AX09, maraviroc, The metabolism of Maraviroc can be decreased when combined with Erythromycin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Erythromycin.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be decreased when combined with Erythromycin.]
[R05CB06, ambroxol, The metabolism of Ambroxol can be decreased when combined with Erythromycin.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be decreased when combined with Erythromycin.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Lidoflazine.]
[J01FF02, lincomycin, The therapeutic efficacy of Erythromycin can be decreased when used in combination with Lincomycin.]
[N06BA13, armodafinil, The metabolism of Erythromycin can be increased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Erythromycin.]
[N02CA07, lisuride, Erythromycin may increase the vasoconstricting activities of Lisuride.]
[A07DA03, loperamide, The excretion of Loperamide can be decreased when combined with Erythromycin.]
[N05BA06, lorazepam, The metabolism of Lorazepam can be decreased when combined with Erythromycin.]
[C10AA02, lovastatin, The serum concentration of Lovastatin can be increased when it is combined with Erythromycin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Erythromycin.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Erythromycin.]
[V04CC02, magnesium sulfate, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Erythromycin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Mannitol can be increased when it is combined with Erythromycin.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Erythromycin.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Erythromycin is combined with Metildigoxin.]
[G03DB03, medrogestone, The metabolism of Medrogestone can be decreased when combined with Erythromycin.]
[P01BC02, mefloquine, The metabolism of Mefloquine can be decreased when combined with Erythromycin.]
[B01AB06, nadroparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Dalteparin.]
[N02AB02, meperidine, The metabolism of Meperidine can be decreased when combined with Erythromycin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Methadone.]
[N05CM01, methaqualone, The metabolism of Methaqualone can be decreased when combined with Erythromycin.]
[G02CB05, metergoline, Erythromycin may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The metabolism of Erythromycin can be decreased when combined with Methimazole.]
[N02BG08, ziconotide, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Erythromycin.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Erythromycin.]
[V04CG05, methylene blue, The serum concentration of Methylene blue can be increased when it is combined with Erythromycin.]
[G02AB01, methylergonovine, Erythromycin may increase the vasoconstricting activities of Methylergometrine.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Erythromycin.]
[H02AB04, methylprednisolone, The serum concentration of Methylprednisolone can be increased when it is combined with Erythromycin.]
[G03EK01, methyltestosterone, The metabolism of Methyltestosterone can be decreased when combined with Erythromycin.]
[N02CA04, methysergide, Erythromycin may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Erythromycin.]
[P01AB01, metronidazole, The metabolism of Metronidazole can be decreased when combined with Erythromycin.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Erythromycin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Erythromycin.]
[S02AA13, miconazole, The metabolism of Erythromycin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Erythromycin.]
[B01AB07, parnaparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Parnaparin.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Erythromycin.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Tinzaparin.]
[C09CA03, valsartan, The excretion of Erythromycin can be decreased when combined with Valsartan.]
[L01XX23, mitotane, The metabolism of Erythromycin can be increased when combined with Mitotane.]
[C01BD01, amiodarone, The metabolism of Erythromycin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Amitriptyline.]
[N02AA01, morphine, The metabolism of Morphine can be decreased when combined with Erythromycin.]
[A04AA05, palonosetron, The metabolism of Palonosetron can be decreased when combined with Erythromycin.]
[L04AB05, certolizumab pegol, The metabolism of Erythromycin can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The excretion of Erythromycin can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The serum concentration of Pazopanib can be increased when it is combined with Erythromycin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Erythromycin.]
[G04CA04, silodosin, The excretion of Silodosin can be decreased when combined with Erythromycin.]
[G03XC01, raloxifene, The excretion of Raloxifene can be decreased when combined with Erythromycin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Erythromycin.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Erythromycin.]
[V03AB15, naloxone, The metabolism of Erythromycin can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Erythromycin can be increased when combined with Anakinra.]
[M02AA12, naproxen, Erythromycin may decrease the excretion rate of Naproxen which could result in a higher serum level.]
[A10BG01, troglitazone, Troglitazone may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Erythromycin.]
[L02BG04, letrozole, The metabolism of Letrozole can be decreased when combined with Erythromycin.]
[A10BX02, repaglinide, The serum concentration of Repaglinide can be increased when it is combined with Erythromycin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Levosimendan.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Erythromycin.]
[N06AX23, desvenlafaxine, The metabolism of Desvenlafaxine can be decreased when combined with Erythromycin.]
[C09CA07, telmisartan, Erythromycin may decrease the excretion rate of Telmisartan which could result in a higher serum level.]
[H05BX02, paricalcitol, The metabolism of Paricalcitol can be decreased when combined with Erythromycin.]
[C08CA04, nicardipine, Erythromycin may decrease the excretion rate of Nicardipine which could result in a higher serum level.]
[C04AE02, nicergoline, Erythromycin may increase the vasoconstricting activities of Nicergoline.]
[C08CA05, nifedipine, Erythromycin may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Nisoldipine.]
[N05CD02, nitrazepam, The metabolism of Nitrazepam can be decreased when combined with Erythromycin.]
[C08CA08, nitrendipine, Erythromycin may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Erythromycin may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N05CF03, zaleplon, The metabolism of Zaleplon can be decreased when combined with Erythromycin.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be decreased when combined with Erythromycin.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Erythromycin.]
[C02KX01, bosentan, Bosentan may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N06AA10, nortriptyline, The serum concentration of Nortriptyline can be increased when it is combined with Erythromycin.]
[G02CA02, nylidrin, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding can be increased when Erythromycin is combined with Reviparin.]
[G01AA01, nystatin, The excretion of Erythromycin can be decreased when combined with Nystatin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Erythromycin.]
[S02AA16, ofloxacin, Erythromycin may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[L04AC04, rilonacept, The metabolism of Erythromycin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Erythromycin.]
[N02AA02, opium, The metabolism of Opium can be decreased when combined with Erythromycin.]
[B01AD07, reteplase, The risk or severity of bleeding can be increased when Erythromycin is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding can be increased when Erythromycin is combined with Ancrod.]
[G04CA02, tamsulosin, The metabolism of Tamsulosin can be decreased when combined with Erythromycin.]
[C01AC01, ouabain, The serum concentration of Ouabain can be increased when it is combined with Erythromycin.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Erythromycin.]
[N02AA05, oxycodone, The metabolism of Oxycodone can be decreased when combined with Erythromycin.]
[N02AA11, oxymorphone, The metabolism of Oxymorphone can be decreased when combined with Erythromycin.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Erythromycin.]
[V04CH30, 4-aminohippuric acid, The excretion of Erythromycin can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding can be increased when Erythromycin is combined with Danaparoid.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be decreased when combined with Erythromycin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Papaverine.]
[H02AB05, paramethasone, The serum concentration of Paramethasone can be increased when it is combined with Erythromycin.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Erythromycin.]
[G04BD11, fesoterodine, The metabolism of Fesoterodine can be decreased when combined with Erythromycin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Penfluridol.]
[M01CC01, penicillamine, The excretion of Penicillamine can be decreased when combined with Erythromycin.]
[S01AA14, penicillin G, The excretion of Benzylpenicillin can be decreased when combined with Erythromycin.]
[N05CA01, pentobarbital, The metabolism of Erythromycin can be increased when combined with Pentobarbital.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Erythromycin.]
[N04BC02, pergolide, Erythromycin may increase the vasoconstricting activities of Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Perhexiline.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Erythromycin.]
[B01AA02, phenindione, The risk or severity of bleeding can be increased when Erythromycin is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Erythromycin.]
[N03AA02, phenobarbital, The metabolism of Erythromycin can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, The risk or severity of bleeding can be increased when Erythromycin is combined with Phenprocoumon.]
[A08AA01, phentermine, The metabolism of Phentermine can be decreased when combined with Erythromycin.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Erythromycin.]
[N03AB02, phenytoin, The metabolism of Erythromycin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Erythromycin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Erythromycin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation and ventricular arrhythmias can be increased when Erythromycin is combined with Pimozide.]
[C10AA05, atorvastatin, The serum concentration of Atorvastatin can be increased when it is combined with Erythromycin.]
[J05AE01, saquinavir, The metabolism of Erythromycin can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The metabolism of Pipotiazine can be decreased when combined with Erythromycin.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Erythromycin can be decreased when combined with Delavirdine.]
[B01AC13, abciximab, The risk or severity of bleeding can be increased when Erythromycin is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding can be increased when Erythromycin is combined with Alteplase.]
[A10BG02, rosiglitazone, Erythromycin may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Erythromycin.]
[L04AC08, canakinumab, The metabolism of Erythromycin can be increased when combined with Canakinumab.]
[J05AE03, ritonavir, The serum concentration of Erythromycin can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The metabolism of Saxagliptin can be decreased when combined with Erythromycin.]
[C10AA08, pitavastatin, The serum concentration of Pitavastatin can be increased when it is combined with Erythromycin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Erythromycin.]
[N05BA11, prazepam, The metabolism of Prazepam can be decreased when combined with Erythromycin.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Erythromycin.]
[S03BA02, prednisolone, The serum concentration of Prednisolone can be increased when it is combined with Erythromycin.]
[H02AB07, prednisone, The serum concentration of Prednisone can be increased when it is combined with Erythromycin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation and hypotension can be increased when Erythromycin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Primaquine.]
[N03AA03, primidone, The metabolism of Erythromycin can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Erythromycin is combined with Procaine.]
[C10AB05, fenofibrate, Erythromycin may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Prochlorperazine.]
[G03DA04, progesterone, Progesterone may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Promazine.]
[G03DB07, promegestone, The metabolism of Promegestone can be decreased when combined with Erythromycin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Erythromycin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Propafenone.]
[R06AX26, fexofenadine, Erythromycin can cause an increase in the absorption of Fexofenadine resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[L01XH02, romidepsin, The serum concentration of Romidepsin can be increased when it is combined with Erythromycin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Erythromycin.]
[N02AC04, propoxyphene, The metabolism of Dextropropoxyphene can be decreased when combined with Erythromycin.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Erythromycin.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be increased when it is combined with Erythromycin.]
[B01AC09, epoprostenol, The risk or severity of bleeding can be increased when Erythromycin is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Erythromycin.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Erythromycin.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Erythromycin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Erythromycin.]
[P01AX05, quinacrine, The metabolism of Quinacrine can be decreased when combined with Erythromycin.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Quinine.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Erythromycin can be increased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Roxithromycin.]
[A07EC01, sulfasalazine, The excretion of Erythromycin can be decreased when combined with Sulfasalazine.]
[S01FA02, scopolamine, The metabolism of Scopolamine can be decreased when combined with Erythromycin.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Erythromycin.]
[V04CC03, sincalide, The excretion of Sincalide can be decreased when combined with Erythromycin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Sotalol.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Erythromycin.]
[C03DA01, spironolactone, Erythromycin may decrease the excretion rate of Spironolactone which could result in a higher serum level.]
[A05AA01, chenodeoxycholic acid, The metabolism of Chenodeoxycholic acid can be decreased when combined with Erythromycin.]
[D11AX24, deoxycholic acid, Deoxycholic acid may increase the excretion rate of Erythromycin which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AB02, hydrocortisone butyrate, The metabolism of Hydrocortisone butyrate can be decreased when combined with Erythromycin.]
[H02CA04, levoketoconazole, The metabolism of Erythromycin can be decreased when combined with Levoketoconazole.]
[A05AA02, ursodiol, Erythromycin may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[N02CA01, dihydroergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[C10AA01, simvastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[G02AB03, ergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[N02CA02, ergotamine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[L01CE02, irinotecan, Irinotecan - CYP3A4 inhibitors]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[C10AA02, lovastatin, HMG Co-A reductase inhibitors - CYP3A4 inhibitors]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[G02AB01, methylergonovine, CYP3A4 inhibitors - ergot alkaloids and derivatives]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
